PEDIATRICS Vol. 108 No. 4 October 2001, pp. 960-964

REVIEW ARTICLE:
Neonatal Hemochromatosis

Karen F. Murray, MD^* and Kris V. Kowdley, MD

From the ^* Department of Pediatrics, Division of Gastroenterology and Nutrition, and  Department of Medicine, Division of Gastroenterology and Hepatology, University of Washington School of Medicine, Seattle, Washington.

Hereditary hemochromatosis is a common autosomal recessive disorder that results in excessive iron deposition in the liver as well as in extrahepatic sites. Symptoms related to hepatic insufficiency, cardiac dysfunction, or endocrinological abnormalities usually present between 40 and 60 years of age. Involvement in adults who are younger than 30 years is uncommon and in children has only rarely been reported.^1-3

Neonatal hemochromatosis (NH), also known as neonatal iron storage disease, is a phenotypically similar disorder; however, its extremely early onset of liver failure makes it notably unique. NH originally was described in 1957,⁴ and >100 cases have been reported. Liver failure in the first 30 days of life is uncommon; neonates represent <2% of children who are listed for liver transplantation,⁵ but of these few patients, NH may be one of the most common causes of liver failure. Despite lack of clear cause and pathogenesis and the possibility that it is not a primary disease state, the syndrome of NH now is widely recognized and universally found to have an aggressive course and carry a poor prognosis.

This article discusses the most common clinical presentation as well as less-common clinical associations. Genetic inheritance and theories that pertain to abnormal iron metabolism versus NH as the final pathway of multiple possible in utero insults also are reviewed. Methods of diagnosis, liver histology, and treatment and prognosis are discussed.

	CLINICAL PRESENTATION

When not stillborn, infants with NH frequently are premature or are small for gestational age. The pregnancy may be complicated by intrauterine growth retardation, oligohydramnios, placental edema, or sometimes polyhydramnios.^6,7 Illness usually is evident within hours of birth, although some have been diagnosed at a few weeks of age.^6,8 Patients have features of liver failure with hypoalbuminemia, hypoglycemia, coagulopathy, low fibrinogen, and, frequently, thrombocytopenia and anemia. If not present at birth, ascites develops shortly thereafter, as does hyperbilirubinemia. Transaminase levels are characteristically low.

Clearly, the onset of the liver disease is in utero, with end-stage liver disease already established even in the prematurely born infant. Hepatocellular synthetic insufficiency can explain the coagulopathy, low fibrinogen, and hypoalbuminemia. The hypoalbuminemia in turn contributes to a low intravascular oncotic pressure, edema, contracted blood volume, oliguria, and resultant oligohydramnios.⁷ The edema and ascites may be attributable to anemia, heart failure, or portal hypertension. The characteristically low transaminases and hypoglycemia that is secondary to poor glycogen stores are evidence of overall hepatocellular loss. The frequently seen anemia probably is multifactorial, caused by severely limited hepatic erythropoiesis, acquired defects in erythrocyte membranes as a result of liver disease, and hypotransferrinemia and low erythropoietin levels as a result of hepatocellular synthetic insufficiency.

	OTHER CLINICAL ASSOCIATIONS

The NH phenotype, with respect to clinical presentation, laboratory abnormalities, liver histology, and parenchymal iron deposition, also has been seen in children who ultimately are diagnosed with ⁴-3-oxosteroid 5-reductase deficiency, a defect in bile acid synthesis.^8,9 Clayton¹⁰ pointed out, however, that this enzyme is labile, and, hence, its activity may be substantially reduced with hepatocyte damage. Consequently, ⁴-3-oxosteroid 5-reductase deficiency may or may not be a primary diagnosis in a subset of NH patients. A report of an infant with NH born to a mother with Sjögren's syndrome and high levels of anti-Ro/SS-A and anti-La/SS-B antibodies raises the possibility of an autoimmune pathophysiology to this condition.¹¹

Most patients with NH do not have other significant congenital abnormalities; however, patients with 2 separate syndromes have been described with some frequency. Four children, 2 pairs of siblings, have been reported with trichomalacia, diarrhea, facial dysmorphology, and some degree of congenital heart disease; Verloes and colleagues^12-14 coined the name "Tricho-Hepato-Enteric syndrome." In addition, 4 patients have been described with NH and renal tubular dysgenesis, also an autosomal recessive condition.^15,16 This supports the belief that NH is the result of an in utero insult to the fetus.

	GENETICS

Family analyses have been conducted to determine whether there is a genetic basis for NH and whether there is a genetic link to hereditary hemochromatosis. Transmission of the disorder has been described as autosomal recessive, codominant, and autosomal dominant with variable penetrance. There now are multiple reports of recurrence of NH in siblings^17-19 and half-siblings.²⁰ In most analyses of family occurrences, an autosomal recessive pattern of inheritance has emerged.^18,19,21 Another observation, however, cannot be ignored. Several women have had infants with NH fathered by different men, yet no man has fathered children with NH with different women. This suggests possible mitochondrial inheritance, an acquired and persistent maternal factor, or gonadal mosaicism for a dominant mutation lethal in spermatogenesis but not in oogenesis.²²

A genetic relationship with hereditary hemochromatosis is an attractive idea because the distribution of parenchymal iron and the liver histology in the 2 conditions are similar. The HFE (hereditary hemochromatosis) gene is mutated in the majority of patients with hereditary hemochromatosis. This gene is located on the short arm of chromosome 6, and there is an association with the HLA-A3 alloantigen. The HFE gene mutation has been found in parents of children with NH,²³ and parents and affected children may share the HLA-A3 alloantigen.^17,19,24,25 Other studies have disputed this link and association, however.²⁶ Furthermore, infants with the HFE gene mutation do not necessarily have NH.²⁷

	IRON METABOLISM

The bulk of the body's iron is as essential iron, specifically heme compounds: enzymes with iron-sulfur complexes. The largest store of essential iron is erythron in red blood cells, the next-largest fraction is as myoglobin in muscle, and the third largest fraction is as mitochondrial enzymes.²⁸ These iron fractions are essential for body functioning. Iron in these forms is relatively stable, limited by the life span of the cells in which it is contained.

Tissue iron is stored primarily in ferritin. Ferritin is a polypeptide sphere that encloses iron atoms. Ferritin is found in cellular cytoplasm and lysosomal membranes. Glycosylated, iron-free ferritin is secreted into the serum from all ferritin-producing cells and therefore reflects tissue iron stores. Ferritin secretion into serum increases, however, under conditions of inflammation, particularly when the inflammation involves ferritin-rich tissues. In lysosomes, the ferritin molecules aggregate and the degraded polypeptides and iron coalesce into hemosiderin, which can be seen with Prussian Blue staining under light microscopy.²⁸

Transferrin, the main molecule that mediates transfer of iron between tissues, is a single polypeptide with 2 iron-binding sites. Occupation of none (apoferric), 1 (monoferric), or both (diferric) of the iron-binding sites determines the degree of iron saturation. Transfer of the iron to tissues occurs by the interaction of the transferrin-iron complex with specific membrane receptors and subsequent internalization of the transferrin-iron complex.²⁸ Fibroblasts from patients with NH synthesize ferritin and transferrin receptors, and iron regulates the cellular expression of ferritin and transferrin receptors to the same degree as do fibroblasts from individuals without NH.²⁴ Furthermore, the intracellular processes by which iron is metabolized are unaffected in NH fibroblasts.²⁴ It is known now that the transferrin receptor interacts with both HFE (hereditary hemochromatosis) protein and 2-microglobulin (2M).²⁹ Proper interaction of these molecules allows for regulated internalization and subsequent cycling back to the cell surface of the transferrin-iron-HFE protein-2M complex, therefore maintaining correct tissue-iron concentrations. In hereditary hemochromatosis, mutation of the HFE gene results in an abnormal HFE protein that does not associate with 2M and after internalization is not transported back to the cell surface.³⁰ HFE protein is expressed in the crypt cells of the small intestine. It is believed that in individuals with homozygosity for specific HFE gene mutations (C282Y and H63D), the mutant HFE is trapped extracellularly, hence impeding the transport of iron via the transferrin-transferrin receptor interaction.³¹ Parkkila et al²⁹ found that the transferrin receptor and HFE protein-2M complex also are located in the apical plasma membrane of the syncytiotrophoblast cells of the fetal placenta, thus playing a role in iron transport across the placenta. Placental iron levels, in turn, may regulate the expression of transferrin receptors on the syncytiotrophoblast apical plasma membrane and therefore maintains steady iron uptake into the placenta.³²

Nontransferrin-bound iron (NTBI) ligands also may play a role in hemochromatosis. In hereditary hemochromatosis, a chelator-inaccessible fraction of NTBI has been observed.³³ The identity of this presumably high-affinity ligand has not yet been elucidated. In the case of hemochromatosis, it is possible that this NTBI-ligand fraction is extruded from the cytoplasm of damaged cells. Cytoferrin (host-associated iron transfer factor), an iron-binding compound of lower molecular weight than transferrin, is found mainly in cellular cytoplasm but also in low concentrations in serum. Cytoferrin concentrations are known to increase with liver disease or in the setting of iron loading.³⁴ Knisely et al³⁴ compared the serum concentration of cytoferrin among adult nonselected women, parturient women, normal infants (cord serum), and an infant with NH. The difference between parturient and nonparturient women was not significant. Cord sera from normal neonates, however, had a cytoferrin concentration twice that of the women, and sera from the NH infant had a concentration 270 times that of the women. The transplacental gradient of cytoferrin suggests that this compound may be involved in maternofetal transport of iron. The dramatic increase in cytoferrin in the NH neonate simply may be secondary to the liver disease, but its possible role in this disorder warrants additional investigation.

	DIAGNOSIS

Diagnosis generally is made after other causes of neonatal liver failure are excluded (Table 1) and confirmatory tests are performed. Serum concentrations of ferritin are elevated in patients with NH; thus, an elevated ferritin will help to confirm the diagnosis. Body-iron stores normally are high in infancy; furthermore, elevated ferritin is nonspecific and simply may represent total body overload, nonspecific liver disease, or inflammation.^7,35 When measured, the iron-binding capacity (transferrin) is low, reflecting the impaired synthetic ability of the liver. The percentage of iron saturation, however, has been reported markedly to exceed the normally high saturation seen in the cord blood of newborns without liver disease (80%),⁷ with saturations of 95% to 100% common.^6,7

Siderosis of the liver is normal in the third trimester but can be distinguished from NH hepatic siderosis by the extrahepatic siderosis with reticuloendothelial sparing. Specifically, although the iron deposition in NH is most notable in the liver, it also is present in the heart, pancreas, exocrine and endocrine organs, intestines, and gastric and salivary glands. The siderosis explicitly spares the reticuloendothelial elements, however, as it does in hereditary hemochromatosis. Siderosis of extrahepatic sites including the salivary glands makes it possible to verify the diagnosis histologically without the need for a liver biopsy. Knisely et al³⁶ showed that siderosis of acinar epithelial cells was found in the minor salivary glands of all patients who proved to have NH and none of 30 patients without liver disease. Salivary gland siderosis also was seen in patients with tyrosinemia, parvovirus B19, rubella, -thalassemia, and renal-hepatic-pancreatic cystic dysplasia of Ivemark, but these generally could be distinguished on other clinical and laboratory grounds.

Because of the paramagnetic influence of ferric ions (Fe³⁺) on the image signal during magnetic resonance imaging (MRI), MRI can be useful in the diagnostic evaluation of an infant with possible NH. The signal alterations caused by the ferric ions cause shortening of the T1 and, more impressive, the T2 relaxation times. Any tissue containing iron therefore will have low signal intensity. In NH with T2-weighted images, the signal intensity of the liver and pancreas will be lower than that of the normal-intensity spleen.³⁷ Furthermore, the more rapid imaging possible with T2 gradient-recalled-echo can be used for morphologic and functional assessment of myocardial siderosis.³⁷ In situations in which a fetus is at risk of having NH, MRI also can be used to evaluate the infant during the third trimester of pregnancy. In this case, fetal liver intensity can be compared with other fetal tissues and with the mother's liver.³⁷

	LIVER HISTOLOGY

Nodular cirrhosis with severe cholestasis typically is found at the time of biopsy or autopsy. It is not unusual to see regenerating nodules separated by wide bands of bland fibrosis containing proliferating bile ducts and multinucleated giant cells.^38,39 Central vein sclerosis with thickened venular walls and lumens either stenosed or occluded by fibrous tissue also is common. The siderosis is always, by definition, significant. Within tubular hepatocytes, hemosiderin occupies the apical cytoplasm adjacent to the bile canaliculi.³⁹ In hepatic giant cells, the iron and bile are more diffusely distributed.³⁹ Extramedullary erythropoiesis, usually obviously apparent in the neonate, is found only in the sinusoids of liver nodules in NH³⁹ and probably contributes to the anemia in these patients. Although less common, hepatocellular carcinoma has been reported in cases of NH at the time of transplantation or autopsy,^3840-42 reinforcing the prenatal onset of this condition.

Whereas the average liver weight is lower in NH than normal livers (reflecting loss of hepatic parenchyma) even when adjustments are made for gestational age and body size, the mean hepatic iron concentration is higher in NH than comparable controls.³⁹ Knisely⁷ found that the range of hepatic iron concentration in patients with NH ranged from 240 to 38 200 µg/g dry weight compared with the average weight of that of a healthy neonate (250 µg/g dry weight). It must be noted, however, that despite the clearly elevated liver iron in most cases, the range overlaps with normal perinatal hepatic iron concentration in some patients. Furthermore, there are conditions other than NH in which the iron content is elevated in the liver and other nonreticuloendothelial organs (Table 2). This elevated iron content in other organs is particularly likely with cirrhosis and may indicate a shunt siderosis similar to that frequently seen in adult liver disease.³⁹

	TREATMENT AND PROGNOSIS

NH is nearly universally fatal, and experience with treatment is limited because many die before diagnosis. Deferoxamine therapy is not efficacious,^38,43 and it has been suggested that its use may potentiate bacterial growth.⁶ Despite early preliminary reports to the contrary,^44,45 deferoxamine combined with an antioxidant cocktail has not proved to be universally successful.

Although experience is very limited, liver transplantation has been successful in treating NH.⁴⁶ In one study of 14 infants with NH treated with an antioxidant cocktail, 5 patients survived to transplantation and 3 were alive 1 year after transplantation.⁶ In most cases, the iron overload resolves slowly after transplantation. In 1 patient, however, iron accumulated in the allograft as early as 7 days posttransplantation and the patient died of cardiac arrhythmias 2 months posttransplantation.⁴² The iron accumulation in the allograft liver was thought to be secondary to redistribution of the preexisting body iron, and the authors speculated that deferoxamine and antioxidant therapy may be beneficial after transplantation.

	CONCLUSION

Top Conclusion References

NH is a dramatic condition that, although rare, may be one of the most common causes of liver failure in the newborn. Its cause is not clear, and there is even controversy over whether it is a unique disease state. It is known, however, that NH can recur in families and has shown inheritance patterns, and it may or may not be related to hereditary hemochromatosis. Furthermore, although medical treatments have not been successful, liver transplantation provides some hope for the families and individuals who are affected. Ongoing research into its cause and pathogenesis eventually will uncover some of the mysteries related to this disease state.

	FOOTNOTES

Received for publication Nov 10, 2000; accepted Mar 19, 2001.

Reprint requests to (K.F.M.) Hepatobiliary Program, Children's Hospital and Regional Medical Center, 4800 Sand Point Wy, NE, Box 5371/CH-24, Seattle, WA 98105-0371. E-mail: kmurra{at}chmc.org

	ABBREVIATIONS

NH, neonatal hemochromatosis; 2M, 2-microglobulin; NTBI, nontransferrin-bound iron; MRI, magnetic resonance imaging.

	REFERENCES

Top Conclusion References

1. Kaikov Y, Wadsworth LD, Hassell E, Dimmick JE, Rogers PCJ Primary hemochromatosis in children: report of three newly diagnosed cases and review of the pediatric literature. Pediatrics 1992; 90:37-42 [Abstract/Free Full Text]
2. Cazzola M, Ascari E, Barosi G, Juvenile idiopathic hemochromatosis: a life threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet 1983; 65:149-154 [CrossRef][Medline]
3. Perkins KW, McInnes IWS, Blackburn CRB, Beal RW Idiopathic hemochromatosis in children: a report of a family. Am J Med 1965; 39:118-126
4. Cottier H Ueber ein der Hämochromatose vergleichbares Krankheitsbild bei Neugeborenen. Schweiz Med Wochenschr 1957; 37:39-43
5. Schneider BL Neonatal liver failure. Curr Opin Pediatr 1996; 8:495-501 [CrossRef][Medline]
6. Sigurdsson L, Reyes J, Kocoshis SA, Hansen TWR, Rosh J, Knisely AS Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies. J Pediatr Gastroenterol Nutr 1998; 26:85-89 [CrossRef][Medline]
7. Knisely AS Neonatal hemochromatosis. Adv Pediatr 1992; 39:383-403 [Medline]
8. Siafakas CG, Jonas MM, Perez-Atayde AR Abnormal bile acid metabolism and neonatal hemochromatosis: a subset with poor prognosis. J Pediatr Gastrenterol Nutr 1997; 25:321-326 [CrossRef][Medline]
9. Shneider BL, Setchell KDR, Whitington PF, Neilson KA, Suchy FJ ⁴-3-oxosteroid 5-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr 1994; 124:234-238 [Medline]
10. Clayton PT ⁴-3-oxosteroid 5-reductase deficiency and neonatal hemochromatosis [letter]. J Pediatr 1994; 125:845-846 [Medline]
11. Schoenlebe J, Buyon JP, Zitelli BJ, Friedman D, Greco MA, Knisely AS Neonatal hemochromatosis associated with maternal autoantibodies against Ro/SS-A and La/SS-B ribonucleoproteins. Am J Dis Child 1993; 147:1072-1075 [Abstract/Free Full Text]
12. Verloes A, Lombet J, Lambert Y, Tricho-Hepato-Enteric syndrome: further delineation of a distinct syndrome with neonatal hemochromatosis phenotype, intractable diarrhea, and hair anomalies. Am J Med Genet 1997; 68:391-395 [CrossRef][Medline]
13. Stankler L, Lloyd D, Pollitt RJ, Gray ES, Thom H, Russell G Unexplained diarrhoea and failure to thrive in two siblings with unusual facies and abnormal scalp hair shafts: a new syndrome. Am J Dis Child 1982; 57:212-216
14. Taucher SC, Bentjerodt R, Hubner ME, Nazer J Multiple malformations in neonatal hemochromatosis. Am J Med Genet 1994; 50:213-214 [CrossRef][Medline]
15. Bale PM, Kan AE, Dorney SFA Renal proximal tubular dysgenesis associated with severe neonatal hemosiderotic liver disease. Pediatr Pathol 1994; 14:479-489 [Medline]
16. Johal JS, Thorp JW, Oyer CE Neonatal hemochromatosis, renal tubular dysgenesis, and hypocalvaria in a neonate. Pediatr Dev Pathol 1998; 1:433-437 [CrossRef][Medline]
17. Silver MM, Beverley DW, Valberg LS, Cutz E, Phillips MJ, Shaheed WA Perinatal hemochromatosis: clinical, morphologic, and quantitative iron studies. Am J Pathol 1987; 128:538-554 [Abstract]
18. Knisely AS, Magid MS, Dische MR, Cutz E Neonatal hemochromatosis. Birth Defects 1987; 23:75-102
19. Dalhøj J, Kiaer H, Wiggers P, Grady RW, Jones RL, Knisely AS Iron storage disease in parents and sibs of infants with neonatal hemochromatosis: 30-year follow-up. Am J Med Genet 1990; 37:342-345 [CrossRef][Medline]
20. Verloes A, Temple IK, Hubert A-F, Recurrence of neonatal haemochromatosis in half sibs born of unaffected mothers. J Med Genet 1996; 33:444-449 [Abstract/Free Full Text]
21. Ferrell L, Schmidt K, Sheffield V, Packman S Neonatal hemochromatosis: genetic counseling based on retrospective pathologic diagnosis. Am J Med Genet 1992; 44:429-433 [CrossRef][Medline]
22. De Boissieu D, Knisely AS. Neonatal hemochromatosis. In: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver Disease in Children, I. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:641-647
23. Glista BA, Bautista A, Prudencio M, Desposito F Neonatal iron storage disease [abstract]. Pediatr Res 1986; 20:410A
24. Knisely AS, Harford JB, Klausner RD, Taylor SR Neonatal hemochromatosis. Am J Pathol 1989; 134:439-445 [Abstract]
25. Colletti RB, Clemmons JW Familial neonatal hemochromatosis with survival. J Pediatr Gastroenterol Nutr 1988; 7:39-45 [Medline]
26. Hardy L, Hansen JL, Kushner JP, Knisely AS Neonatal hemochromatosis: genetic analysis of transferrin-receptor, H-apoferritin, and L-apoferritin loci, and of the human leucocyte antigen class 1 region. Am J Pathol 1990; 137:149-153 [Abstract]
27. Merryweather-Clarke A, Simonsen H, Shearman JD, Pointon JJ, Nørgaard-Pedersen B, Robson KJH A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Hum Mutat 1999; 13:154-159 [CrossRef][Medline]
28. Finch CA, Huebers H Perspectives in iron metabolism. N Engl J Med 1982; 306:1520-1528 [Medline]
29. Parkkila S, Waheed A, Britton RS, Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A 1997; 94:13198-13202 [Abstract/Free Full Text]
30. Waheed A, Parkkila S, Zhou XY, Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with 2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 1997; 94:12384-12389 [Abstract/Free Full Text]
31. Bacon BB, Powell LW, Adams PC, Kresina TF, Hoofnagle JH Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116:193-207 [CrossRef][Medline]
32. Bierings MB, Baert MR, van Eijk HG, van Dijk JP Transferrin receptor expression and the regulation of placental iron uptake. Mol Cell Biochem 1991; 100:31-38 [CrossRef][Medline]
33. Breuer W, Hershko C, Cabantchik ZI The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23:185-192 [CrossRef][Medline]
34. Knisely AS, Grady RW, Kramer EE, Jones RL Cytoferrin, maternofetal iron transport, and neonatal hemochromatosis. Am J Clin Pathol 1989; 92:755-759 [Medline]
35. Prieto J, Barry M, Sherlock S Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology 1975; 68:525-533 [Medline]
36. Knisely AS, O'Shea PA, Stocks JF, Dimmick JE Oropharyngeal and upper respiratory tract mucosal-gland siderosis in neonatal hemochromatosis: an approach to biopsy diagnosis. J Pediatr 1988; 113:871-874 [CrossRef][Medline]
37. Oddone M, Bellini C, Bonacci W, Toma P, Serra G Diagnosis of neonatal hemochromatosis with MR imaging and duplex Doppler sonography. Eur Radiol 1999; 9:1882-1885 [CrossRef][Medline]
38. Jonas MM, Kaweblum YA, Fojaco R Neonatal hemochromatosis: failure of deferoxamine therapy. J Pediatr Gastroenterol Nutr 1987; 6:984-988 [Medline]
39. Silver MM, Valberg LS, Cutz E, Lines LD, Phillips MJ Hepatic morphology and iron quantitation in perinatal hemochromatosis. Am J Pathol 1993; 143:1312-1325 [Abstract]
40. Silver MM, Cave CT, Kirpalani H Perinatal hemochromatosis. Pediatr Pathol 1989; 9:203-210 [Medline]
41. Oliveira MG, Silva AC, Moreira R, Azevedo A, Da Silva LJ A case of neonatal haemochromatosis. Acta Paediatr 1998; 87:102-104 [CrossRef][Medline]
42. Egawa H, Berquist W, Garcia-Kennedy R, Cox K, Knisely AS, Esquivel CO Rapid development of hepatocellular siderosis after liver transplantation for neonatal hemochromatosis. Transplantation 1996; 62:1511-1513 [CrossRef][Medline]
43. Lund DP, Lillehei CW, Kevy S, Liver transplantation in newborn liver failure: treatment for neonatal hemochromatosis. Transplant Proc 1993; 25:1068-1071 [Medline]
44. Shamieh I, Kibort PK, Suchy FJ, Freese DK Antioxidant therapy for neonatal iron storage disease (NISD) [abstract]. Pediatr Res 1993; 33:109
45. Chase MC, Riedinger D Neonatal hemochromatosis: a case report. Neonatal Netw 1995; 14:7-12 [Medline]
46. Rand EB, McClenathan DT, Whitington PF Neonatal hemochromatosis: report of successful orthotopic liver transplantation. J Pediatr Gastroenterol Nutr 1992; 15:325-329 [Medline]